# LabClear Presentation Business Review — 2026-10-12

## Review scope and independence

- Review type: read-only business and pricing assessment of the local Business Report, HTML deck, source map, demo catalog/plans, cited GL-05 review, and current browser-UAT manifest.
- Candidate HEAD inspected: `38e39f03a8a21a294001cbb2bd146a4c7ea611eb`; the worktree was dirty. This first review occurred before the corrections listed below.
- Reviewer: generic read-only explorer subagent applying the `marketing-strategy` and `pricing-offers` skills. The registered agent catalog has no dedicated Marketing Agent; this is not a configured named Marketing Agent. The orchestration tool did not establish separate reviewer-account authentication, so account independence is unverified and should be treated as reduced.
- No source edits, external browsing, customer contact, live price changes, API calls, or spend were performed by the reviewer.

## Findings

| Priority | Finding | Evidence | Disposition |
|---|---|---|---|
| P1 | Business report wording described catalog prices as coming from a “real catalog” while the report and local data mark them as demo values. | `business_data/catalog.json` has `is_demo: true`; `business_data/plans.json` has `is_demo: true`. | Corrected to “demo catalog” / “simulated catalog”; no live offer is implied. |
| P2 | The deck Appendix A4 and source map listed a UAT start time different from the raw run manifest. | Raw `browser-uat-final-20261012-04/browser-uat.json` records `started_at=2026-10-12T05:46:45.127Z`. | Corrected Appendix A4 and source map to the raw manifest timestamp. |
| P2 | A cited GL-05 marketing review belongs to the older `73d24b9` worktree, not the current `38e39f0` candidate. | `gl05-settlement-role-fence-20261011/marketing-review-gl05-20261011.md` states its inspected revision. | Re-labelled as historical advice and added this current review record as a separate source. |

An additional MAIN evidence cross-check found that Appendix A4 carried the diff hash from UAT `final03`. It was replaced with the empty-diff SHA-256 in the cited `final04` raw manifest; the appendix now labels it explicitly as the diff hash.

## Business assessment

- The core deck has a coherent prototype-demo narrative. Its 10 core slides estimate 8:30 of speaking time plus a 0:30 reserve; no spoken rehearsal evidence exists.
- The UAT result is supportable as local workflow evidence: 37 PASS, 0 FAIL, synthetic fixtures, and mocked LLM/OCR. It does not establish customer demand, clinical/model quality, or commercial readiness.
- The package and Plus prices match configured demo data. No customer willingness-to-pay, purchase, margin, CAC, or unit-cost evidence supports them as viable live offers. The report appropriately leaves commercialization and price changes open.
- Hospital-package research rows are dated local records; included/excluded test details are incomplete for the listed offers, so they do not establish comparable package value. External provider pages were not opened in this review.
- The current Plus configuration leaves the AI-read limit uncapped/unspecified; cost and transparent fair-use limits remain pre-commercialization risks.

## Re-review

Follow-up reviewer result: PASS on the three initial findings. The reviewer confirmed the demo wording, timestamp against the raw manifest, historical/current review labels, and independence caveat. The additional diff-hash correction was verified separately by MAIN against the raw JSON. This is a read-only source review, not customer research, financial validation, a configured Marketing Agent approval, or a release approval.
